PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 261 filers reported holding PACIRA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.85 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,089,171 | -66.5% | 35,501 | -56.3% | 0.00% | -100.0% |
| Q2 2023 | $3,255,968 | +57.5% | 81,257 | +60.4% | 0.00% | 0.0% |
| Q1 2023 | $2,066,986 | +10.6% | 50,649 | +4.7% | 0.00% | 0.0% |
| Q4 2022 | $1,868,184 | +219.3% | 48,386 | +339.9% | 0.00% | – |
| Q3 2022 | $585,000 | -68.8% | 11,000 | -65.7% | 0.00% | -100.0% |
| Q2 2022 | $1,872,000 | -64.2% | 32,101 | -53.2% | 0.00% | 0.0% |
| Q1 2022 | $5,232,000 | +134.9% | 68,544 | +85.2% | 0.00% | – |
| Q4 2021 | $2,227,000 | -2.8% | 37,011 | -9.5% | 0.00% | -100.0% |
| Q3 2021 | $2,290,000 | +29.3% | 40,895 | +40.1% | 0.00% | – |
| Q2 2021 | $1,771,000 | +224.4% | 29,182 | +274.1% | 0.00% | – |
| Q1 2021 | $546,000 | -71.6% | 7,800 | -75.7% | 0.00% | -100.0% |
| Q4 2020 | $1,923,000 | +327.3% | 32,127 | +329.4% | 0.00% | – |
| Q3 2020 | $450,000 | -48.1% | 7,482 | -54.7% | 0.00% | – |
| Q2 2020 | $867,000 | +76.2% | 16,521 | +52.1% | 0.00% | -100.0% |
| Q4 2019 | $492,000 | +61.3% | 10,860 | +35.8% | 0.00% | 0.0% |
| Q3 2019 | $305,000 | -62.3% | 8,000 | -57.4% | 0.00% | -50.0% |
| Q4 2018 | $809,000 | -45.1% | 18,798 | -37.3% | 0.00% | -33.3% |
| Q3 2018 | $1,473,000 | -9.5% | 29,962 | -41.0% | 0.00% | -25.0% |
| Q2 2018 | $1,628,000 | +225.0% | 50,800 | +363.2% | 0.00% | +300.0% |
| Q4 2017 | $501,000 | +73.4% | 10,968 | +80.9% | 0.00% | 0.0% |
| Q2 2017 | $289,000 | -90.4% | 6,064 | -90.8% | 0.00% | -92.3% |
| Q1 2017 | $3,004,000 | +219.6% | 65,868 | +126.3% | 0.01% | +225.0% |
| Q4 2016 | $940,000 | -7.8% | 29,107 | -2.3% | 0.00% | -20.0% |
| Q3 2016 | $1,020,000 | +347.4% | 29,804 | +593.9% | 0.01% | +400.0% |
| Q1 2016 | $228,000 | -80.7% | 4,295 | -72.1% | 0.00% | -85.7% |
| Q4 2015 | $1,181,000 | +214.1% | 15,379 | +262.2% | 0.01% | +133.3% |
| Q4 2014 | $376,000 | -51.4% | 4,246 | -46.8% | 0.00% | -62.5% |
| Q3 2014 | $774,000 | -47.0% | 7,985 | -49.8% | 0.01% | -57.9% |
| Q2 2014 | $1,460,000 | +305.6% | 15,892 | +208.6% | 0.02% | +375.0% |
| Q1 2014 | $360,000 | – | 5,150 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |